8.7% growth won't reach 15–20%—the math requires a strong H2

Punjab Chemicals reported solid EBITDA growth and margin expansion in Q1, but the headline masks a critical shortfall: revenue grew just 8.7%, less than half the 15–20% pace management guided for the full year. To hit that FY27 target, H2 (quarters 2–4) needs to deliver an aggressive 18–24% growth rebound. The call reveals why that's a bet, not a forecast.

Domestic revenue declined 3.1% YoY, squeezed by weak Indian monsoon and pricing pressure. Exports surged 27.7%, but management acknowledged the jump came from better supply planning in Q4—Q4 inventory buildup to meet peak-season demand, not a durable shift in customer demand. Stripped of that inventory benefit, organic growth is flatter than the headline suggests.

EBITDA grew 18.8% to ₹40.8 Cr, a surprise on the upside. Gross margin expanded 355 basis points to 36.6%, but management conceded that 3–4% of the 9% revenue growth came from pricing—gains unlikely to persist as markets normalize. The underlying efficiency improvements are real and sustainable; the pricing benefit is not.

MoU timeline slipped. Management reframed three specialty chemical products from 'commercialization in FY27' to 'commercial lots supplied in Q1 with volume ramp in Q4.' The shift reflects a 3–6 month customer testing cycle now embedded in the timeline. Only two of three products are at commercial stage; the third lags further back.

New products are tracking, not accelerating. At 14% of revenue with 40% YoY growth, they're on pace toward the FY27 target of 15–18% but not outpacing it. The pipeline remains robust (25+ molecules, 4–5 commercialized annually), but near-term ramps depend on execution of customer testing cycles and approvals.

EBITDA and Greenfield CAPEX guidance unchanged. Management reaffirmed the path to 15% EBITDA margin over 2–3 years and the goal to start Greenfield CAPEX within FY27. No site secured yet, but commitment is firm.

The stock rose 1.04% on day 1 but faded to –3.82% by day 3 and held there by day 5—a clear market verdict on the headline numbers. Traders saw through the EBITDA pop and focused on the revenue miss and MoU delays, both of which expose material execution risk on the 15–20% FY27 guidance.

FII ownership added 285 basis points QoQ to 5.86%, a constructive signal, but the total position remains shallow—barely above the DII's 0.63%. Volume is declining, signaling traders lack conviction. At ₹1134, the stock is down 26% from its all-time high but only 29% above its 52-week low; RSI at 46.7 shows neutral momentum. The technicals offer no story. Valuation will turn on H2 revenue delivery.